Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
98 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03724747 | Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 63 | BayerINDUSTRY | 3 | Nov 8, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 |
| clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT06063343 | Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145 | completed | Phase 1 | 50 | Novakand Pharma ABINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02994771 | A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema | terminated | Phase 1 | 15 | Herantis Pharma Plc.INDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT02678299 | Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | unknown | Phase 1 / Phase 2 | 60 | University of AarhusOTHER | 5 | Aug 4, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | AbbVieINDUSTRY | 10 | Apr 14, 2022 | clinicaltrials |
| NCT03505944 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma(VALERIA) | unknown | Phase 1 / Phase 2 | 59 | Nordic Lymphoma GroupNETWORK | 4 | Oct 13, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03315546 | Radiotherapy Delivery in Deep Inspiration for Pediatric Patients(TEDDI) | recruiting | Phase 1 / Phase 2 | 25 | Rigshospitalet, DenmarkOTHER | 2 | Oct 9, 2020 | clinicaltrials |
| NCT02264418 | Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours(KIDES-203) | completed | Phase 1 | 84 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT03035591 | ODM-207 in Patients With Advance Solid Tumours(BETIDES) | completed | Phase 1 / Phase 2 | 36 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Oct 15, 2019 | clinicaltrials |
| NCT02367547 | Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL | unknown | Phase 1 / Phase 2 | 117 | Joint Authority for Päijät-Häme Social and Health CareOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02472977 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors(CXCessoR4) | terminated | Phase 1 / Phase 2 | 61 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT00963534 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.(LENA-BERIT) | completed | Phase 1 / Phase 2 | 51 | Lund University HospitalOTHER | 4 | Mar 12, 2018 | clinicaltrials |
| NCT02004106 | A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 110 | Hoffmann-La RocheINDUSTRY | 8 | Mar 6, 2018 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT00927147 | Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 17 | Boneca CorporationINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT02442063 | Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | completed | Phase 1 | 15 | BayerINDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01849666 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01598129 | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | completed | Phase 1 | 12 | Targovax OyINDUSTRY | 1 | Oct 24, 2016 | clinicaltrials |
| NCT02063334 | The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression(VitDbol) | completed | Phase 1 | 35 | University of Eastern FinlandOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT02149342 | Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL | completed | Phase 1 / Phase 2 | 14 | Joint Authority for Päijät-Häme Social and Health CareOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT02369029 | BAY1238097, First in Man | terminated | Phase 1 | 8 | BayerINDUSTRY | 6 | Mar 9, 2016 | clinicaltrials |
| NCT00913263 | An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate(2-HOF) | completed | Phase 1 / Phase 2 | 24 | Lidds ABINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00515931 | Radiation Therapy as Palliative Treatment of GIST(GIST-RT) | completed | Phase 1 / Phase 2 | 25 | Heikki JoensuuOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT00976508 | Figitumumab Combined With Pegvisomant For Advanced Solid Tumors | terminated | Phase 1 | 24 | PfizerINDUSTRY | 4 | Dec 13, 2013 | clinicaltrials |
| NCT00114790 | Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment Head and Neck Tumors | completed | Phase 1 / Phase 2 | 30 | Boneca CorporationINDUSTRY | 1 | May 6, 2013 | clinicaltrials |
| NCT01205321 | PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers | completed | Phase 1 | 19 | Lantheus Biosciences Ltd.INDUSTRY | 3 | Jan 21, 2013 | clinicaltrials |
| NCT01458847 | Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 | 12 | BioCis Pharma LtdINDUSTRY | 1 | Nov 12, 2012 | clinicaltrials |
| NCT00493675 | Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage | withdrawn | Phase 1 | — | Tampere UniversityOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00237900 | Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer | terminated | Phase 1 / Phase 2 | 34 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00239291 | Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00239304 | Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials